Related Experiment Video

Updated: Dec 20, 2025

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.1K

The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma

Simin Kiany1, Douglas Harrison2, Nancy Gordon3

  • 1Department of Pediatrics Research, MD Anderson Cancer Center, Houston, TX, USA.

Advances in Experimental Medicine and Biology
|June 3, 2020
PubMed

Insights

Targeting the Fas/FasL pathway with gemcitabine and entinostat may improve outcomes for metastatic osteosarcoma (OS). This approach aims to increase Fas expression on OS cells, reducing lung metastasis and enhancing patient prognosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Metastatic osteosarcoma (OS) has a poor prognosis with limited therapeutic advancements.
  • Novel molecular targets are crucial for improving treatment outcomes in refractory OS.
  • The Fas/FasL pathway presents a potential therapeutic target for osteosarcoma.

Purpose of the Study:

  • To investigate the potential of modulating the Fas/FasL pathway for treating refractory osteosarcoma.
  • To evaluate the efficacy of combining gemcitabine and entinostat in upregulating Fas expression on OS cells.

Main Methods:

  • Preclinical data suggests Fas expression inversely correlates with OS metastatic potential.
  • FasL in the lung induces cell death in OS cells expressing Fas.
  • Gemcitabine and entinostat (HDAC inhibitor) upregulate Fas expression on OS cells.

Main Results:

  • Upregulation of Fas expression on osteosarcoma cells is a key mechanism.
  • Targeting the Fas/FasL pathway may decrease pulmonary metastasis of OS.
  • Improved outcomes are anticipated with this therapeutic strategy.

Conclusions:

  • Modulating the Fas/FasL pathway offers a promising strategy for refractory osteosarcoma.
  • Combination therapy with gemcitabine and entinostat is under clinical investigation.
  • This approach holds potential for improving survival in patients with metastatic OS.
Keywords:
Fas/FasLGemcitabineHistone deacetylase inhibitorsOsteosarcoma

More Related Videos

Assays for Validating Histone Acetyltransferase Inhibitors09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

6.9K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.5K